Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Year: 2021
Type: conference-abstract
Source: Blood
Institutions: Dartmouth–Hitchcock Medical Center, Rocky Mountain Cancer Centers, Weill Cornell Medicine, The University of Kansas Cancer Center, Texas Oncology, Prisma Health, IHA Hematology Oncology Consultants, Mayo Clinic, Bristol-Myers Squibb (United States), Justus-Liebig-Universität Gießen, Willamette Valley Cancer Institute and Research Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3211871624
